Here are the 424B prospectus supplements from Lipocine Inc. (LPCN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LPCN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LPCN filings page.
LivePerson, Inc. is offering up to $50,000,000 of common stock pursuant to a sales agreement with A.G.P./Alliance Global Partners.
The supplement increases the prior aggregate program (previously $10,616,169) to $50,000,000, which includes 1,603,431 shares previously sold for an aggregate purchase price of $10,615,576. The supplement states there remains $39,384,424 available for sale from and after the date of this prospectus supplement dated February 26, 2026.